Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs Moderna, Inc. (MRNA) Price & Performance

Liberty Media Corporation Series C Liberty Formula One Common StockTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Liberty Media Corporation Series C Liberty Formula One Common Stock vs Moderna, Inc. — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B), while Moderna, Inc. trades at $223.39 (market cap $86.33B). The key difference: Moderna, Inc. is far larger — about 3.7× Liberty Media Corporation Series C Liberty Formula One Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and Moderna, Inc. for 59 Days on average.

FWONKMRNA
Market Cap
$23.11B$86.33B
Volume
3,394,59613,361,426
Sector
MediaHealth
52-Week High
$106.66$226.30
52-Week Low
$81.42$22.36
Typical Hold Time
0 Days59 Days
Enterprise Value
$26.57B$82.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Liberty Media Corporation Series C Liberty Formula One Common Stock

No Aura AI signal available yet.

Moderna, Inc.

Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.

The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FWONK
100% Buy0% Sell
Avg holding period · 0 Days
MRNA
83% Buy17% Sell
Avg holding period · 59 Days

About Liberty Media Corporation Series C Liberty Formula One Common Stock

Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.

Read more on FWONK →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →